The Italian real-life post-stroke spasticity survey: Unmet needs in the management of spasticity with botulinum toxin type A

Alessandro Picelli, Alessio Baricich, Carlo Cisari, Stefano Paolucci, Nicola Smania, Giorgio Sandrini, Marco Aguggia, Enrico Alfonsi, Roberto Antonacci, Fabrizio Balestrieri, Michele Bertoni, Donatella Bonaiuti, Calogera Butera, Chiara Cesaretti, Carmelo Chisari, Paola Cicinelli, Marco Frontoni, Marialuisa Gandolfi, Pamela Latino, Giorgio MaggioniMario Manca, Paolo Manganotti, Salvatore Misceo, Marcello Romano, Andrea Santamato, Antonio Santoro, Alessandro Specchia, Carlo Trompetto, on behalf of the Italian Real-Life Survey Group

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about “real-life” post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5% felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8% use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7% of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7%), physiatrists (58.3%), family doctors (50%), stroke unit physicians (25%), patients and caregivers (79.2%). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients’ clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalFunctional Neurology
Volume32
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Type A Botulinum Toxins
Stroke
Physicians
Lower Extremity
Injections
Physical Therapists
Electromyography
Checklist
Upper Extremity
Italy
Caregivers
Electric Stimulation
Quality of Life
Surveys and Questionnaires

Keywords

  • Botulinum toxins
  • Disease management
  • Muscle spasticity
  • Rehabilitation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Picelli, A., Baricich, A., Cisari, C., Paolucci, S., Smania, N., Sandrini, G., ... on behalf of the Italian Real-Life Survey Group (2017). The Italian real-life post-stroke spasticity survey: Unmet needs in the management of spasticity with botulinum toxin type A. Functional Neurology, 32(2), 89-96. https://doi.org/10.11138/FNeur/2017.32.2.089

The Italian real-life post-stroke spasticity survey : Unmet needs in the management of spasticity with botulinum toxin type A. / Picelli, Alessandro; Baricich, Alessio; Cisari, Carlo; Paolucci, Stefano; Smania, Nicola; Sandrini, Giorgio; Aguggia, Marco; Alfonsi, Enrico; Antonacci, Roberto; Balestrieri, Fabrizio; Bertoni, Michele; Bonaiuti, Donatella; Butera, Calogera; Cesaretti, Chiara; Chisari, Carmelo; Cicinelli, Paola; Frontoni, Marco; Gandolfi, Marialuisa; Latino, Pamela; Maggioni, Giorgio; Manca, Mario; Manganotti, Paolo; Misceo, Salvatore; Romano, Marcello; Santamato, Andrea; Santoro, Antonio; Specchia, Alessandro; Trompetto, Carlo; on behalf of the Italian Real-Life Survey Group.

In: Functional Neurology, Vol. 32, No. 2, 2017, p. 89-96.

Research output: Contribution to journalArticle

Picelli, A, Baricich, A, Cisari, C, Paolucci, S, Smania, N, Sandrini, G, Aguggia, M, Alfonsi, E, Antonacci, R, Balestrieri, F, Bertoni, M, Bonaiuti, D, Butera, C, Cesaretti, C, Chisari, C, Cicinelli, P, Frontoni, M, Gandolfi, M, Latino, P, Maggioni, G, Manca, M, Manganotti, P, Misceo, S, Romano, M, Santamato, A, Santoro, A, Specchia, A, Trompetto, C & on behalf of the Italian Real-Life Survey Group 2017, 'The Italian real-life post-stroke spasticity survey: Unmet needs in the management of spasticity with botulinum toxin type A', Functional Neurology, vol. 32, no. 2, pp. 89-96. https://doi.org/10.11138/FNeur/2017.32.2.089
Picelli, Alessandro ; Baricich, Alessio ; Cisari, Carlo ; Paolucci, Stefano ; Smania, Nicola ; Sandrini, Giorgio ; Aguggia, Marco ; Alfonsi, Enrico ; Antonacci, Roberto ; Balestrieri, Fabrizio ; Bertoni, Michele ; Bonaiuti, Donatella ; Butera, Calogera ; Cesaretti, Chiara ; Chisari, Carmelo ; Cicinelli, Paola ; Frontoni, Marco ; Gandolfi, Marialuisa ; Latino, Pamela ; Maggioni, Giorgio ; Manca, Mario ; Manganotti, Paolo ; Misceo, Salvatore ; Romano, Marcello ; Santamato, Andrea ; Santoro, Antonio ; Specchia, Alessandro ; Trompetto, Carlo ; on behalf of the Italian Real-Life Survey Group. / The Italian real-life post-stroke spasticity survey : Unmet needs in the management of spasticity with botulinum toxin type A. In: Functional Neurology. 2017 ; Vol. 32, No. 2. pp. 89-96.
@article{03ee448358ef4bbc8e8ea4dfc6f5e174,
title = "The Italian real-life post-stroke spasticity survey: Unmet needs in the management of spasticity with botulinum toxin type A",
abstract = "The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about “real-life” post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5{\%} felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8{\%} use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7{\%} of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7{\%}), physiatrists (58.3{\%}), family doctors (50{\%}), stroke unit physicians (25{\%}), patients and caregivers (79.2{\%}). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients’ clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.",
keywords = "Botulinum toxins, Disease management, Muscle spasticity, Rehabilitation",
author = "Alessandro Picelli and Alessio Baricich and Carlo Cisari and Stefano Paolucci and Nicola Smania and Giorgio Sandrini and Marco Aguggia and Enrico Alfonsi and Roberto Antonacci and Fabrizio Balestrieri and Michele Bertoni and Donatella Bonaiuti and Calogera Butera and Chiara Cesaretti and Carmelo Chisari and Paola Cicinelli and Marco Frontoni and Marialuisa Gandolfi and Pamela Latino and Giorgio Maggioni and Mario Manca and Paolo Manganotti and Salvatore Misceo and Marcello Romano and Andrea Santamato and Antonio Santoro and Alessandro Specchia and Carlo Trompetto and {on behalf of the Italian Real-Life Survey Group}",
year = "2017",
doi = "10.11138/FNeur/2017.32.2.089",
language = "English",
volume = "32",
pages = "89--96",
journal = "Functional Neurology",
issn = "0393-5264",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "2",

}

TY - JOUR

T1 - The Italian real-life post-stroke spasticity survey

T2 - Unmet needs in the management of spasticity with botulinum toxin type A

AU - Picelli, Alessandro

AU - Baricich, Alessio

AU - Cisari, Carlo

AU - Paolucci, Stefano

AU - Smania, Nicola

AU - Sandrini, Giorgio

AU - Aguggia, Marco

AU - Alfonsi, Enrico

AU - Antonacci, Roberto

AU - Balestrieri, Fabrizio

AU - Bertoni, Michele

AU - Bonaiuti, Donatella

AU - Butera, Calogera

AU - Cesaretti, Chiara

AU - Chisari, Carmelo

AU - Cicinelli, Paola

AU - Frontoni, Marco

AU - Gandolfi, Marialuisa

AU - Latino, Pamela

AU - Maggioni, Giorgio

AU - Manca, Mario

AU - Manganotti, Paolo

AU - Misceo, Salvatore

AU - Romano, Marcello

AU - Santamato, Andrea

AU - Santoro, Antonio

AU - Specchia, Alessandro

AU - Trompetto, Carlo

AU - on behalf of the Italian Real-Life Survey Group

PY - 2017

Y1 - 2017

N2 - The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about “real-life” post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5% felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8% use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7% of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7%), physiatrists (58.3%), family doctors (50%), stroke unit physicians (25%), patients and caregivers (79.2%). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients’ clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.

AB - The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about “real-life” post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5% felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8% use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7% of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7%), physiatrists (58.3%), family doctors (50%), stroke unit physicians (25%), patients and caregivers (79.2%). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients’ clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.

KW - Botulinum toxins

KW - Disease management

KW - Muscle spasticity

KW - Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=85021901271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021901271&partnerID=8YFLogxK

U2 - 10.11138/FNeur/2017.32.2.089

DO - 10.11138/FNeur/2017.32.2.089

M3 - Article

AN - SCOPUS:85021901271

VL - 32

SP - 89

EP - 96

JO - Functional Neurology

JF - Functional Neurology

SN - 0393-5264

IS - 2

ER -